Author: Rupani, Hitasha; Murphy, Anna; Bluer, Katie; Renwick, Charlotte; McQuitty, Peter; Jackson, David J; Heaney, Liam G; Chaudhuri, Rekha; Menzies-Gow, Andrew; Calvert, James; Siddiqui, Salman
Title: Biologics in Severe Asthma- Which one, When and Where? Cord-id: wrkvx4z5 Document date: 2021_7_21
ID: wrkvx4z5
Snippet: Biologics have transformed the treatment of patients with type 2 (T2)-inflammation driven severe asthma (1). In appropriately selected patients, biologic use reduces asthma exacerbations and reliance on maintenance oral steroids (mOCS) and improves lung function and quality of life. The decision to initiate a biologic is usually led by specialist multi-disciplinary teams (MDTs).
Document: Biologics have transformed the treatment of patients with type 2 (T2)-inflammation driven severe asthma (1). In appropriately selected patients, biologic use reduces asthma exacerbations and reliance on maintenance oral steroids (mOCS) and improves lung function and quality of life. The decision to initiate a biologic is usually led by specialist multi-disciplinary teams (MDTs).
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date